10x Genomics Inc. (TXG)
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)
Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG's valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution.
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.
10x Genomics Q2 Earnings Call Highlights
10x Genomics NASDAQ: TXG reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from a year earlier.
10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.28 per share a year ago.
10x Genomics (TXG) Upgraded to Buy: Here's Why
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
